3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Stomach Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Nasopharyngeal Carcinoma
3
Carcinoma, Hepatocellular
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Nasopharyngeal Neoplasms
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Non Squamous Non-small Cell Lung Cancer
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Motor Activity
1
Gastric Cancer Stage
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
B-cell Malignancies
1
Advanced Squamous Non-Small Cell Lung Carcinoma
1
Advanced Squamous Non Small Cell Lung Cancer
1
Advanced Non-squamous Non-small-cell Lung Cancer
1
Interventions
Fluorouracil
16
Cisplatin
11
Radiotherapy
8
Oxaliplatin
8
Leucovorin
8
Neoadjuvant Therapy
5
Capecitabine
5
Paclitaxel
4
Nivolumab
4
Docetaxel
4
Trastuzumab
3
Carboplatin
3
dehydroftorafur
2
Radiation
2
Irinotecan
2
Epirubicin
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
zolbetuximab
1
zimberelimab
1
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
pertuzumab
1
pembrolizumab
1
gastrin immunogen
1
Taxes
1
Surgical Procedures, Operative
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma Of Esophagus
×
tislelizumab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled